+
Granules India Completes Acquisition of Senn Chemicals
ECONOMY & POLICY

Granules India Completes Acquisition of Senn Chemicals

Granules India Ltd. has officially closed the acquisition of Senn Chemicals AG, a Switzerland-based CDMO specialising in peptide development and manufacturing. This strategic move marks Granules’ entry into the peptide therapeutics segment and contract development and manufacturing (CDMO) services, bolstering its innovation-led growth strategy. 

The acquisition, executed through Granules’ wholly owned subsidiary Granules Peptides Pvt. Ltd., involves a 100% equity stake purchase from the founding Senn family. 

Headquartered in Dielsdorf, Switzerland, Senn Chemicals brings over six decades of expertise in Liquid-Phase and Solid-Phase Peptide Synthesis (LPPS & SPPS), serving pharmaceutical, cosmetic, amino acid derivative (AAD), and theragnostic markets. 

Dr. Krishna Prasad Chigurupati, Chairman and MD of Granules India, highlighted the deal as a “pivotal step” in the company’s evolution into a science- and innovation-led enterprise. He emphasised the synergy between Senn’s peptide specialisation and Granules’ global manufacturing capabilities to drive high-quality, next-gen treatments in areas such as GLP-1 receptor agonists, anti-diabetic, and anti-obesity therapies. 

The acquisition also marks Granules’ formal entry into the CDMO sector, enhancing its global footprint with access to regulated markets, top-tier European scientific talent, and advanced R&D capabilities. Joint development initiatives in peptide APIs are already underway, with an expanded pipeline in the works. 

Advisors on the deal included Stifel Nicolaus India (financial), Loyens & Loeff (legal), Deloitte (financial and tax diligence), and Kroll (valuation). 

This acquisition strengthens Granules’ innovation capabilities and positions it as a key player in the rapidly growing complex therapeutics and CDMO markets. 


(BSE)     

Granules India Ltd. has officially closed the acquisition of Senn Chemicals AG, a Switzerland-based CDMO specialising in peptide development and manufacturing. This strategic move marks Granules’ entry into the peptide therapeutics segment and contract development and manufacturing (CDMO) services, bolstering its innovation-led growth strategy. The acquisition, executed through Granules’ wholly owned subsidiary Granules Peptides Pvt. Ltd., involves a 100% equity stake purchase from the founding Senn family. Headquartered in Dielsdorf, Switzerland, Senn Chemicals brings over six decades of expertise in Liquid-Phase and Solid-Phase Peptide Synthesis (LPPS & SPPS), serving pharmaceutical, cosmetic, amino acid derivative (AAD), and theragnostic markets. Dr. Krishna Prasad Chigurupati, Chairman and MD of Granules India, highlighted the deal as a “pivotal step” in the company’s evolution into a science- and innovation-led enterprise. He emphasised the synergy between Senn’s peptide specialisation and Granules’ global manufacturing capabilities to drive high-quality, next-gen treatments in areas such as GLP-1 receptor agonists, anti-diabetic, and anti-obesity therapies. The acquisition also marks Granules’ formal entry into the CDMO sector, enhancing its global footprint with access to regulated markets, top-tier European scientific talent, and advanced R&D capabilities. Joint development initiatives in peptide APIs are already underway, with an expanded pipeline in the works. Advisors on the deal included Stifel Nicolaus India (financial), Loyens & Loeff (legal), Deloitte (financial and tax diligence), and Kroll (valuation). This acquisition strengthens Granules’ innovation capabilities and positions it as a key player in the rapidly growing complex therapeutics and CDMO markets. (BSE)     

Next Story
Real Estate

Ashar Arize Attracts Lenskart, Clove Dental and More to Kalwa

Ashar Group has announced that Lenskart and Clove Dental will soon open high-street outlets at its flagship residential project, Ashar Arize in Kalwa, redefining the locality’s retail profile. The two national brands will operate from 600 sq. ft. spaces at Ashar Arize, adding healthcare and lifestyle credibility to Kalwa, which is rapidly emerging as a self-sustaining micromarket. The retail plaza spans 20,000 sq. ft. with units ranging from 300 to 800 sq. ft., offering prime frontage and strong connectivity to market hubs. Located near the station, it ensures steady footfall supported ..

Next Story
Infrastructure Transport

KMRL Invites Bids For Metro Phase 2 Station Works

Kochi Metro Rail Limited (KMRL) has invited bids for completing the balance works related to the construction of entry and exit buildings at Civil Station Junction and Cochin SEZ Metro Station, as part of Phase 2 of the Kochi Metro project.Phase 2 covers a single corridor — the Pink Line — running 11.2 km between JLN Stadium and Infopark II, with 11 stations. The latest tender is aimed at finalising station access works, excluding architectural and building service components.According to tender documents, the estimated cost of the contract is Rs 1.99 billion. The pre-bid meeting is schedu..

Next Story
Infrastructure Transport

Tamil Nadu Clears Preparatory Work For New Chennai Metro Line

The Tamil Nadu government has granted administrative sanction for the preparatory work on the 21.76-km Koyambedu–Avadi–Pattabiram metro corridor. This approval allows Chennai Metro Rail Limited (CMRL) to begin land acquisition, utility shifting, and other groundwork while awaiting clearance from the Union government.The State government had already approved the project in May and submitted the detailed project report to the Centre. However, the Ministry of Housing and Urban Affairs has also requested a Comprehensive Mobility Plan (CMP) before granting final approval.According to an order i..

Advertisement

Subscribe to Our Newsletter

Get daily newsletters around different themes from Construction world.

STAY CONNECTED

Advertisement

Advertisement

Advertisement

Talk to us?